2025-23702Proposed RuleSignificant

Medicare's New Trick: Benchmarking Drugs Against Global Prices

Published Date: 12/23/2025

Proposed Rule

Summary

The GLOBE Model is a new plan to help Medicare pay less for certain medicines by using a global price benchmark. This change affects Medicare patients and drug makers, aiming to save money while keeping care quality high. Comments on this plan are open until February 23, 2026, so everyone has a chance to weigh in before it moves forward.

Analyzed Economic Effects

4 provisions identified: 2 benefits, 1 costs, 1 mixed.

Manufacturers must pay GLOBE rebates based on global prices

CMS proposes mandatory participation for all manufacturers of Part B rebatable drugs that are designated as GLOBE Model drugs; those manufacturers would pay GLOBE Model rebates into the Medicare Part B account when the specified amount exceeds a benchmark based on international drug pricing. CMS states the benchmark-based GLOBE Model rebate would not be less than any rebates owed under the existing Medicare Part B Drug Inflation Rebate Program, and manufacturers may submit a Suggestion of Error only for mathematical errors.

CMS estimates multi-billion dollar Medicare savings

CMS estimates the GLOBE Model would reduce overall Medicare Part B net spending by $11.9 billion over the 7-year model period, including about $8.4 billion in Medicare Part B FFS savings, $7.5 billion in Medicare Advantage savings, and about $4.0 billion in premium offset impacts; CMS also estimates about $1.0 billion in Medicaid savings (roughly $0.7 billion federal and $0.3 billion state). When annualized, CMS estimates approximately $2.3 billion in Medicare Part B FFS savings over the 7-year period.

Selected Medicare patients get lower coinsurance

About 25 percent of traditional Medicare Part B fee-for-service beneficiaries in selected geographic areas would be placed in the GLOBE Model cohort. When those beneficiaries receive an included GLOBE Model drug on an applicable date of service, their coinsurance would be reduced (for example, CMS gives an example where a $100 Medicare allowed amount with a reduced coinsurance of 10 percent results in $10 owed by the beneficiary and $90 paid by Medicare, instead of the usual $20/$80 split).

CMS selects cohort; beneficiaries cannot appeal selection

CMS would select which beneficiaries are in the GLOBE Model cohort (based on a beneficiary's address of record in selected geographic areas) and selection would not be subject to appeal; beneficiaries must have traditional Medicare Part B FFS as their primary payer and must not be enrolled in Medicare Advantage, a section 1876 cost plan, or certain prepayment plans to be eligible for cohort inclusion. Providers and suppliers would continue to buy and bill for GLOBE Model drugs as usual, but providers must reduce beneficiary coinsurance when the GLOBE Model reduced coinsurance applies.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
Comments Due
Effective Date
12/23/2025
2/23/2026
10/1/2026

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Centers for Medicare & Medicaid Services
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register

Take It Personal

Get Your Personalized Policy View

Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.

Already have an account? Sign in